Inactivated hepatitis A vaccine: Long-term antibody persistence

Vaccine

Volumn 15, Issue 6-7, 1997, Pages 612-615

  Wiedermann, G ^a   Kundi, M ^a   Ambrosch, F ^a   Safary, A ^b   D'Hondt, E ^b   Delem, A ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

active immunization; two component model; vaccination schedule

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; INACTIVATED VIRUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS A; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

ADULT; FEMALE; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS A VIRUS, HUMAN; HEPATITIS ANTIBODIES; HUMANS; MALE; TIME FACTORS; VACCINES, INACTIVATED; VIRAL HEPATITIS VACCINES;

EID: 0031003644     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(96)00242-3     Document Type: Article

References (20)

1. André, F.E., Hepburn, A. and D'Hondt, E. Inactivated candidate vaccines for hepatitis A. Progr. Med. Virol. 1990, 17, 72-95
2. Ellerbeck, E., Lewis, J., Midthun, K. et al. Safety and Immunogenicity of an Inactivated Hepatitis A Vaccine. In: Proceedings of the 1990 International Symposion on Viral Hepatitis and Liver Disease, Contemporary Issues and Future Prospects (Eds Hollinger, B., Lemon, St.M. and Margolis, H.). Williams and Wilkins, Baltimore, 1991, pp. 91-93
3. Glück, R., Mischler, R., Brantschen, S., Just, M., Althaus, B. and Cryz, S.J.Jr Immunopotentiating reconstituted influenza virosome vaccine delivery system for immunisation against hepatitis A. J. Clin. Invest. 1992, 90, 2491-2495
4. Pellegrini, V., Fineschi, N. and Matteucci, G. et al. Preparation and immunogenicity of an inactivated hepatitis A vaccine. Vaccine 1993, 11, 383-387
5. Goilav, Ch., Zuckerman, J. and Lafranz, M. et al. Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study. J. Med. Virol. 1995, 46, 287-292
6. Ambrosch, F., Frisch-Niggemeyer, W. and Kremsner, P. et al. Persistence of vaccine-induced antibodies to hepatitis B surface antigen and the need for booster vaccination in adult subjects. Postgraduate Med. J. 1987, 63 suppl. 2, 129-135
7. Wiedermann, G., Ambrosch, F., André, F.E., D'Hondt, E., Delem, A. and Safary, A. Persistence of vaccine-induced antibody to hepatitis A virus. Vaccine 1992, 10 suppl. 1, 129-131
8. Berger, R. and Just, M. Vaccination against hepatitis A: control 3 years after the first vaccination. Vaccine 1992, 10, 295
9. Van Damme, P., Thoelen, S., Gramm, M., De Groote, K., Safary, A. and Meheus, A. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity and long-term antibody persistence. J. Med. Virol. 1994, 44, 446-451
10. Wiedermann, G., Ambrosch, F. and Kollaritsch, H. et al. Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers. Vaccine 1990, 8, 581-584
11. Delem, A., Safary, A., Denamur, F., Hauser, P. and D'Hondt, E. Characterization of the immune response of volunteers vaccinated with a killed vaccine against hepatitis A. Vaccine 1993, 11, 479-484
12. Karpinsky, K.F., Hayward, S. and Tryphonas, H. Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA). J. Immunol. Meth. 1987, 103, 189-194
13. Ambrosch, F., Wiedermann, G., André, F.E., D'Hondt, E., Delem, A. and Safary, A. Comparison of HAV antibodies induced by vaccination, passive immunisation and natural infection. In: Proceedings of the 1990 International Symposion on Viral Hepatitis and Liver Disease, Contemporary Issues and Future Prospects (Eds Hollinger, B., Lemon, St.M. and Margolis, H.). Williams and Wilkins, Baltimore, 1991, pp. 98-100
14. Stapleton, J.T., Jansen, R. and Lemon, S.M. Neutralizing antibody to hepatitis A virus in immune serum globulin and in the sera of human recipients of immune serum globulin. Gastroenterology 1985, 89, 637-642
15. Innis, B.L., Snitbhan, R. and Kunasol, P. et al. Protection against hepatitis A by an inactivated vaccine. J. Am. Med. Assoc. 1994, 271, 1328-1334
16. Delem, A., Vandercuylen, C., Safary, A., Just, M. and Desmijter, J. IgM and IgG antibody response after immunisation with a killed HAV vaccine: effect of dose and of the vaccination scheme. 8th International Congress of Virology, Berlin, 1990
17. Roitt, I.M., Brostoff, J. and Male, D.K. Kurzes Lehrbuch der Immunologie. Thieme, Stuttgart, 1995, p. 44
18. Jilg, W., Schmidt, M., Deinhardt, F. and Zachoval, R. Hepatitis B vaccination: how long does protection last? The Lancet 1984, 458
19. Grob, P.J., Dufek, A. and Joller-Jemelka, H.I. Hepatitis B-Impfung: Wann ist eine Booster-Injektion nötig? Schweizerische medizinische Wochenschrift 1985, 115, 394-402
20. Bona, C.A. Idiotype network. In: Encyclopedia of Immunology (Eds Roitt, I.M. and Delves, P.J.). Academic Press, London, 1992, pp. 729-736